12:34 PM EST, 01/13/2025 (MT Newswires) -- BioMarin Pharmaceutical ( BMRN ) filed a lawsuit against Ascendis Pharma ( ASND ) in the Unified Patent Court in Munich, claiming infringement of European patent EP 3 175 863 B1.

The patent covers long-acting variants of C-Type Natriuretic Peptide, BioMarin said Monday in a statement.

Ascendis' TransCon CNP investigational product and its development program in Germany and Europe are alleged to infringe on BioMarin's patent, which was confirmed by the European Patent Office's Opposition Division in 2024.

A decision is anticipated in 12 to 15 months, BioMarin said. The Unified Patent Court has jurisdiction over European patents for 18 European member states

Ascendis couldn't be reached immediately for comment.

Shares of BioMarin fell 0.9% in recent Monday trading, and Ascendis rose 4.3%.

Price: 66.76, Change: -0.62, Percent Change: -0.92